Article
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
PloS one - 1 Jan 2016
Asselah Tarik, Thompson Alex J, Flisiak Robert, Romero-Gomez Manuel, Messinger Diethelm, Bakalos Georgios, Shiffman Mitchell L
Abstract excerpt
BACKGROUND: Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult genotype to eradicate and PegIFN/RBV remains an effective option. The goal of this study was to devise a simple...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.